An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Terminated
Amplyx Pharmaceuticals
Phase 2
This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of
APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in
patients aged 18 years and over with limited antifungal treatment options.
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Terminated
Pfizer
Phase 2
This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of
APX001 for the treatment of candidemia and/or invasive candidiasis caused by C. auris in
patients aged 18 years and over with limited antifungal treatment options.
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
Completed
Amplyx Pharmaceuticals
Phase 1
This is a Phase 1, open-label study to evaluate the drug-drug interaction potential of a
strong CYP3A4 inhibitor (itraconazole) and a pan-CYP inducer (rifampin) on APX001 in two
parallel groups of healthy subjects.
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
Completed
Pfizer
Phase 1
This is a Phase 1, open-label study to evaluate the drug-drug interaction potential of a
strong CYP3A4 inhibitor (itraconazole) and a pan-CYP inducer (rifampin) on APX001 in two
parallel groups of healthy subjects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
